View More View Less
  • 1 Aesculap Akadémia, Budapest, Halmi u. 20–22., 1115
  • | 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
  • | 3 Szent Imre Egyetemi Oktatókórház, Budapest
  • | 4 B. Braun Avitum Dialízishálózat, Budapest
Open access

Absztrakt

Az időskori hypertonia kezelésére vonatkozó szakmai javaslatokban jelentős változások következtek be az elmúlt másfél évtizedben. A szerzők célja, hogy nemzetközi összehasonlításban bemutassák a különböző cardiovasculariskockázat-besorolású időskori hypertonia kezelésének jelenleg érvényes magyar irányelveit, nyomon követve az ajánlásokban bekövetkezett változásokat és ismertetve a változásokat előidéző bizonyítékokat. Elemzésükhöz a 2001 és 2015 között megjelent magyar, európai és amerikai hypertoniakezelési irányelveket és szakmai állásfoglalásokat használták fel. Sokáig a felnőttkori hypertoniában alkalmazandó kezelési küszöb és célértékek vonatkoztak idősekre is, cardiovascularis kockázatot növelő társbetegségekben pedig fokozatosan szigorodtak az elvárások; mígnem az új klinikai vizsgálatok eredményei és a korábbiak újraértékelése a célvérnyomás-követelmények enyhítéséhez, valamint korosztály-specifikus ajánlásokhoz vezettek. Az összehasonlított régiók jelenleg érvényes irányelveinek javaslatai különböznek időskori diabetesben, vesebetegségben és albuminuriában a vonatkozó célértéket, a béta-blokkolók alkalmazását és az időskor alsó határát illetően. Egyetértenek azonban abban, hogy a 140–150/<90 Hgmm vérnyomásnál alacsonyabb célérték hasznosságára nincs elég bizonyíték, és további vizsgálatok szükségesek az időskorban, aggkorban és különböző kockázati csoportokban az optimális célvérnyomás tisztázására. Orv. Hetil., 2016, 157(7), 247–259.

  • 1

    Glynn, R. J., Field, T. S., Rosner, B., et al.: Evidence for a positive linear relation between blood pressure and mortality in elderly people. Lancet, 1995, 345(8953), 825–829.

  • 2

    Mulrow, C. D., Cornell, J. A., Herrera, C. R., et al.: Hypertension in the elderly. Implications and generalizability of randomized trials. JAMA, 1994, 272(24), 1932–1938.

  • 3

    Kiss, I., (ed.): Treatment of hypertension disease. [A hypertoniabetegség ellátása.] Hypertonia és Nephrologia, 2015, 19(Suppl. 1), 1–38. [Hungarian]

  • 4

    Mancia, G., Fagard, R., Narkiewicz, K., et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens., 2013, 31(7), 1281–1357.

  • 5

    Aronow, W. S., Fleg, J. L., Pepine, C. J., et al.: ACCF/AHA 2011 Expert consensus document on hypertension in the elderly. American College of Cardiology Foundation (ACCF), American Heart Association (AHA). JACC, 2011, 57(20), 2037–2114.

  • 6

    James, P. A., Oparil, S., Carter, B. L., et al.: Evidence-based guideline for the management of high blood pressure in sdults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA, 2014, 311(5), 507–520.

  • 7

    Kiss, I., Farsang, Cs. (eds.): Guideline for treatment of hypertension. [A hypertonia ellátásának szakmai és szervezeti irányelvei.] Hypertonia és Nephrologia, 2001, 5(Suppl. 1), 1–44. [Hungarian]

  • 8

    Kiss, I. (ed.): Guideline for treatment of hypertension. [A hypertoniabetegség kezelésének szakmai irányelvei.] Hypertonia és Nephrologia, 2004, 8(Suppl. 2), 13–52. [Hungarian]

  • 9

    Kiss, I. (ed.): Guideline for treatment of hypertension. [A hypertoniabetegség kezelésének szakmai irányelvei.] Hypertonia és Nephrologia, 2005, 9(Suppl. 5), 157–164. [Hungarian]

  • 10

    Kiss, I. (ed.): Guideline for treatment of hypertension in adult and pediatric population. [A hypertoniabetegség felnőttkori és gyermekkori kezelésének szakmai és szervezeti irányelvei.] Hypertonia és Nephrologia, 2008, 12(Suppl. 2), 85–156. [Hungarian]

  • 11

    Kiss, I. (ed.): Guideline for treatment of hypertension in adult and pediatric population. [A hypertoniabetegség felnőttkori és gyermekkori kezelésének szakmai és szervezeti irányelvei.] Hypertonia és Nephrologia, 2009, 13(Suppl. 2), 81–168. [Hungarian]

  • 12

    2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens., 2003, 21(6), 1011–1053.

  • 13

    Mancia, G., De Backer, G., Dominiczak, A., et al.: 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 2007, 28(12), 1462–1536.

  • 14

    Chobanian, A. V., Bakris, G. L., Black, H. R., et al.: The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. JAMA, 2003, 289(19), 2560–2571.

  • 15

    Mancia, G., Laurent, S., Agabiti-Rosei, E., et al.: Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens., 2009, 27(11), 2121–2158.

  • 16

    Amery, A., Birkenhäger, W., Brixko, P., et al.: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet, 1985, 1(8442), 1349–1354.

  • 17

    Dahlöf, B., Lindholm, L. H., Hansson, L., et al.: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet, 1991, 338(8778), 1281–1285.

  • 18

    Coope, J., Warrender, T. S.: Randomised trial of treatment of hypertension in elderly patients in primary care. Br. Med. J., 1986, 293(6555), 1145–1151.

  • 19

    SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 1991, 265(24), 3255–3264.

  • 20

    MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ, 1992, 304(6824), 405–412.

  • 21

    Lithell, H., Hansson, L., Skoog, I., et al.: The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens., 2003, 21(5), 875–886.

  • 22

    Staessen, J. A., Fagard, R., Thijs, L., et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997, 350(9080), 757–764.

  • 23

    Liu, L., Wang, J. G., Gong, L., et al., for the Systolic Hypertension in China (Syst-China) Collaborative Group: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J. Hypertens., 1998, 16(12 Pt 1), 1823–1829.

  • 24

    JATOS Study Group: Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertension Res., 2008, 31(12), 2115–2127.

  • 25

    Ogihara, T., Saruta, T., Rakugi, H., et al.: Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension, 2010, 56(2), 196–202.

  • 26

    Zhang, Y., Zhang, X., Liu, L., et al.: Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur. Heart J., 2011, 32(12), 1500–1508.

  • 27

    Gong, L., Zhang, W., Zhu, Y., et al.: Shanghai trial of nifedipine in the elderly (STONE). J. Hypertens., 1996, 14(10), 1237–1245.

  • 28

    Mohebi, R., Mohebi, A., Ghanbarian, A., et al.: Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population? J. Am. Soc. Hypertens., 2014, 8(7), 491–497.

  • 29

    Gueyffier, F., Bulpitt, C., Boissel, J. P., et al.: Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet, 1999, 353(9155), 793–796.

  • 30

    Bulpitt, C. J., Beckett, N. S., Cooke, J., et al.: Results of the pilot study for the Hypertension in the Very Elderly Trial. J. Hypertens., 2003, 21(12), 2409–2417.

  • 31

    Beckett, N. S., Peters, R., Fletcher, A. E., et al., for the HYVET Study Group: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med., 2008, 358(18), 1887–1898.

  • 32

    Beckett, N., Peters, R., Tuomilehto, J., et al.: Immediate and late benefits of treating very elderly people with hypertension: results from the active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ, 2011, 344, d7541.

  • 33

    The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362(9386), 782–788.

  • 34

    Denardo, S. J., Gong, Y., Nichols, W. W., et al.: Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am. J. Med., 2010, 123(8), 719–726.

  • 35

    Ruggenenti, P., Perna, A., Loriga, G., et al.: Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet, 2005, 365(9463), 939–946.

  • 36

    Wright, J. T. Jr., Bakris, G., Greene, T., et al.: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002, 288(19), 2421–2431.

  • 37

    Klahr, S., Levey, A. S., Beck, G. J., et al., for the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N. Engl. J. Med., 1994, 330(13), 877–884.

  • 38

    Upadhyay, A., Earley, A., Haynes, S. M., et al.: Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann. Intern. Med., 2011, 154(8), 541–548.

  • 39

    Sarnak, M. J., Greene, T., Wang, X., et al.: The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann. Intern. Med., 2005, 142(5), 342–351.

  • 40

    Appel, L. J., Wright, J. T. Jr., Greene, T., et al., for the AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N. Engl. J. Med., 2010, 363(10), 918–929.

  • 41

    Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345(12), 851–860.

  • 42

    Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345(12), 861–869.

  • 43

    Arguedas, J. A., Perez, M. I., Wright, J. M.: Treatment blood pressure targets for hypertension. Cochrane Database Syst. Rev., 2009, (3), CD004349.

  • 44

    Adler, A. I., Stratton, I. M., Neil, H. A., et al.: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ, 2000, 321(7258), 412–419.

  • 45

    Schrier, R. W., Estacio, R. O., Esler, A., et al.: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int., 2002, 61(3), 1086–1097.

  • 46

    Patel, A., ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007, 370(9590), 829–840.

  • 47

    The ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med., 2010, 362(17), 1575–1585.

  • 48

    Cooper-DeHoff, R. M., Gong, Y., Handberg, E. M., et al.: Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA, 2010, 304(1), 61–68.

  • 49

    Cederholm, J., Gudbjörnsdottir, S., Eliasson, B., et al.: Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP-II). J. Hypertens., 2012, 30(10), 2020–2030.

  • 50

    Hansson, L., Zanchetti, A., Carruthers, S. G., et al., for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351(9118), 1755–1762.

  • 51

    UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br. Med. J., 1998, 317(7160), 703–713.

  • 52

    Messerli, F. H., Grossman, E., Goldbourt, U.: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA, 1998, 279, 1903–1907.

  • 53

    Dahlof, B., Devereux, R. B., Kjeldsen, S. E., et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 995–1003.

  • 54

    Dalhöf, B., Sever, P. S., Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366(9489), 895–906.

  • 55

    Wiysonge, C. S., Bradley, H. A., Volmink, J., et al.: Beta-blockers for hypertension. Cochrane Database Syst. Rev., 2012, 11, CD002003.

  • 56

    Law, M. R., Morris, J. K., Wald, N. J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009, 338, b1665.

  • 57

    Holman, R. R., Paul, S. K., Bethel, M. A., et al.: Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med., 2008, 359(15), 1565–1576.

  • 58

    Blackburn, D. F., Lamb, D. A., Eurich, D. T., et al.: Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. J. Hypertens., 2007, 25(7), 1499–1505.

  • 59

    Hansson, L., Lindholm, L. H., Ekbom, T., et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 1999, 354(9192), 1751–1756.

  • 60

    Turnbull, F., Neal, B., Ninomiya, T., et al., Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Br. Med. J., 2008, 336(7653), 1121–1123.

  • 61

    ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288(23), 2981–2997.

  • 62

    Kjeldsen, S. E., Dahlöf, B., Devereux, R. B., et al.: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA, 2002, 288(12), 1491–1498.

  • 63

    Papademetriou, V., Farsang, C., Elmfeldt, D., et al.: Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol., 2004, 44(6), 1175–1180.

  • 64

    ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med., 2008, 358(15), 1547–1559.

  • 65

    Fried, L. F., Emanuele, N., Zhang, J. H., et al., for the VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med., 2013, 369(20), 1892–1903.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 44 36 3
PDF Downloads 65 50 2